Q & A: Pfizer – the Sandwich story, filling the gap
This article was originally published in Scrip
Executive Summary
When downsizing strikes R&D in the middle of a debt crisis, its not good news to find out that the emptying site also needs flood defenses. But as Paul Carter, who led the task force that responded to Pfizer’s exodus from Sandwich tells Scrip’s Eleanor Malone, local and central government and business can work together to reduce the immediate impact, prevent a business disaster, and to manage the process.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.